Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

And Now For The Real Biosimilar Opportunity: Antibodies And Complex Biologics

Executive Summary

With patents on blockbuster drugs – including Roche/Biogen Idec Inc.'s Rituxan (rituximab), Amgen Inc./Pfizer Inc.'s Enbrel (etanercept) and Roche's Herceptin (trastuzumab) – due to expire in key markets within the next three years, there's a renewed buzz around biosimilars as industry players seek to grab a share of this multi-billion dollar opportunity.
Advertisement

Related Content

Biosimilars Guidance On Interferon Beta From EMA Foreshadows Possible Joint EU/U.S. Approach
Amgen, Watson Aim For First Joint Oncology Biosimilar In 2017 To Open International Doors
Amgen, Watson Aim To Launch First Joint Oncology Biosimilar In U.S. In 2017
Biosimilar Insulin Worth The Effort? For Some, Maybe
Biosimilars Marketing: Companies Must Find "Sweet Spot" Between Generic And Innovator Approach
Complex Biologics: Near-Term Patent Expiry Dates
Merck Lands Late-Stage Enbrel Biosimilar In Deal With South Korea's Hanwha
Biosimilars Pathway Dilemma: When Should Sponsors Pick (k) Before (a)?
Biosimilars: Nearly The End Already, Or Is The Best Yet To Come?
Samsung Looks To Mirror Fellow Korean Pharma Celltrion's Path From CMO To Biosimilars Developer With Quintiles JV

Topics

Advertisement
UsernamePublicRestriction

Register

PS053520

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel